Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Clinical trial NCT07154706 · RECRUITING

Trial details

NCT number: NCT07154706
Sponsor: Nuvation Bio Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer (NSCLC)

Start date: 2025-08-21
Primary completion: 2030-08-30
Enrollment: 180

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.